Ligand Reports Fourth Quarter and Full Year 2023 Financial Results Feb 27, 2024 07:00AM
ALDX DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action – ALDX Sep 25, 2023 10:41AM
ROSEN, A TOP RANKED LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALDX Sep 14, 2023 07:34PM
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – ALDX Sep 3, 2023 05:18PM
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALDX Aug 26, 2023 01:40PM
View Older Stories

Aug 21, 2023 11:25AM ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALDX
Aug 16, 2023 11:33AM ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – ALDX
Aug 8, 2023 04:01PM Ligand Reports Second Quarter 2023 Financial Results
Jun 15, 2023 07:02AM Aldeyra Therapeutics (ALDX) Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE‑2 Trial of Reproxalap in Allergic Conjunctivitis
Jun 15, 2023 07:00AM Aldeyra Therapeutics Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE‑2 Trial of Reproxalap in Allergic Conjunctivitis
Jun 14, 2023 04:01PM Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 INVIGORATE‑2 Trial in Allergic Conjunctivitis
Jun 2, 2023 07:00AM Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
May 4, 2023 07:00AM Aldeyra Therapeutics Reports First-Quarter 2023 Financial Results and Recent Corporate Highlights
Apr 13, 2023 07:00AM Aldeyra Therapeutics Completes Enrollment in Phase 3 INVIGORATE-2 Clinical Trial in Allergic Conjunctivitis
Apr 6, 2023 07:00AM Aldeyra Therapeutics Enrolls First Patient in Phase 2 Clinical Trial of ADX-629 in Atopic Dermatitis
Mar 30, 2023 07:00AM Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX-629 in Chronic Cough
Mar 16, 2023 07:00AM Aldeyra Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of ADX‑2191 in Retinitis Pigmentosa
Mar 9, 2023 07:00AM Aldeyra Therapeutics Reports Full-Year 2022 Financial Results and Recent Corporate Highlights
Mar 2, 2023 07:00AM Aldeyra Therapeutics (ALDX) Accepts for Priority Review ADX-2191
Mar 2, 2023 07:00AM FDA Accepts for Priority Review ADX-2191 New Drug Application for the Treatment of Primary Vitreoretinal Lymphoma
Mar 1, 2023 07:00AM Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Full-Year 2022 Financial Results and Discuss Recent Corporate Highlights
Feb 28, 2023 07:17AM Aldeyra Therapeutics (ALDX) Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease
Feb 28, 2023 07:00AM Aldeyra Therapeutics Announces Positive Top-Line Results from 12-Month Safety Clinical Trial of Reproxalap in Patients with Dry Eye Disease
Feb 23, 2023 07:05AM Aldeyra Therapeutics (ALDX) to Begin ADX‑246 and ADX‑248 Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy
Feb 23, 2023 07:00AM Aldeyra Therapeutics Announces Next-Generation RASP-Modulator Drug Candidates Expected to Begin Clinical Trials for Systemic Immune-Mediated Diseases and Geographic Atrophy
Feb 16, 2023 07:03AM Aldeyra Therapeutics (ALDX) Advances ADX‑629 Into New Phase 2 Trials
Feb 16, 2023 07:00AM Aldeyra Therapeutics Advances Investigational Oral RASP Modulator ADX‑629 Into New Phase 2 Systemic Disease Trials
Feb 9, 2023 07:00AM Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
Feb 7, 2023 07:01AM Aldeyra Therapeutics (ALDX) Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease
Feb 7, 2023 07:00AM Aldeyra Therapeutics Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye Disease
Dec 21, 2022 07:00AM Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal Lymphoma
Dec 13, 2022 08:04AM Aldeyra Therapeutics (ALDX) Announces RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial
Dec 13, 2022 08:00AM Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial
Dec 1, 2022 08:01AM Aldeyra Therapeutics (ALDX) Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA
Dec 1, 2022 08:00AM Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA
Nov 29, 2022 08:02AM Aldeyra Therapeutics (ALDX) Submits NDA to FDA for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease
Nov 29, 2022 08:00AM Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for Reproxalap for the Treatment of Signs and Symptoms of Dry Eye Disease
Nov 10, 2022 07:00AM Aldeyra Therapeutics Reports Third-Quarter 2022 Financial Results and Recent Corporate Highlights
Nov 3, 2022 08:00AM Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Third-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
Oct 26, 2022 08:00AM Aldeyra Therapeutics Announces Oral Presentation of Phase 3 Data at the American Academy of Optometry 2022 Annual Meeting
Oct 6, 2022 07:04AM Aldeyra Therapeutics (ALDX) Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
Oct 6, 2022 07:00AM Aldeyra Therapeutics Achieves Primary Endpoint in Part 1 of Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
Oct 5, 2022 04:05PM Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy
Sep 14, 2022 08:02AM Aldeyra Therapeutics (ALDX) Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones
Sep 14, 2022 08:00AM Aldeyra Therapeutics Announces Positive Dry Eye Disease Pre-NDA Meeting with the FDA and Highlights Upcoming Corporate Milestones
Sep 7, 2022 08:00AM Aldeyra Therapeutics to Participate in Upcoming Investor Conferences
Aug 5, 2022 07:00AM Aldeyra Therapeutics Reports Second-Quarter 2022 Financial Results and Recent Corporate Highlights
Jul 29, 2022 08:00AM Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2022 Financial Results and Discuss Recent Corporate Highlights
Jul 12, 2022 07:02AM Aldeyra Therapeutics (ALDX) Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial
Jul 12, 2022 07:00AM Aldeyra Therapeutics Achieves Primary Endpoints in Dry Eye Disease Chamber Crossover Clinical Trial
Jul 11, 2022 04:05PM Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Dry Eye Disease Chamber Crossover Clinical Trial of Reproxalap
Jun 9, 2022 08:00AM Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
Jun 8, 2022 07:01AM Aldeyra Therapeutics (ALDX) Reports Phase 3 TRANQUILITY‑2 Study Achieves Primary Endpoint
Jun 8, 2022 07:00AM Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 TRANQUILITY‑2 Trial in Dry Eye Disease and Intends to Submit New Drug Application for Symptoms and Three Sign Endpoints of Dry Eye Disease
Jun 7, 2022 04:05PM Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 TRANQUILITY-2 Trial in Dry Eye Disease
View Older Stories